Northland analyst Carl Byrnes downgraded Oncternal Therapeutics to Market Perform from Outperform with a price target of $2, down from $25, after the company announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer, and ONCT-808, its ROR1-targeting autologous CAR T program for the treatment of patients with aggressive B-cell lymphoma, and to explore strategic alternatives
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics downgraded to Hold from Buy at Brookline
- Oncternal Therapeutics trading resumes
- Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
- Oncternal terminates ONCT-534, ONCT-808 studies, explores strategic alternatives
- Oncternal Therapeutics trading halted, news pending